Cannabis Users With Schizophrenia Had Lower Rates of Metabolic Syndrome | Research

The takeaway

Among people with schizophrenia, those who tested positive for THC had significantly lower rates of metabolic syndrome and central obesity compared to non-users.

Psychiatrists, metabolic health researchers, and people interested in cannabis and metabolic effects.

42.5% vs 60.5% metabolic syndrome prevalence

What the researchers found

In 988 CATIE study participants with schizophrenia, THC-positive individuals (14.8%) had significantly lower metabolic syndrome prevalence (42.5% vs 60.5%, p < 0.001). After adjusting for confounders, cannabis use remained associated with reduced MetS odds (adjusted OR 0.64, 95% CI: 0.44-0.93, p = 0.02) and lower waist circumference (adjusted OR 0.61, 95% CI: 0.41-0.91).

Why it matters

Metabolic syndrome is extremely common in schizophrenia (often exceeding 50%) and drives cardiovascular mortality. Understanding why cannabis users have lower rates could reveal metabolic pathways worth targeting, though the cross-sectional design limits causal interpretation.

The numbers in context

988 participants, 14.8% THC-positive by hair testing. MetS prevalence: 42.5% in cannabis users vs 60.5% in non-users. Adjusted OR for MetS: 0.64 (p = 0.02). Adjusted OR for elevated waist circumference: 0.61 (p = 0.02). Cannabis users also had lower weight, BMI, and triglycerides.

How the study worked

Cross-sectional analysis of 988 participants with DSM-IV schizophrenia from the CATIE study. Cannabis use was objectively measured via hair testing for THC. Metabolic syndrome was defined by International Diabetes Federation criteria. Multivariable logistic regression adjusted for demographics, smoking, and other substance use.

What this study cannot tell us

Cross-sectional design cannot determine causation. Cannabis users may differ from non-users in ways not fully captured by covariates (diet, activity levels, illness severity). Hair testing captures recent use but not lifetime exposure patterns.

How to read the evidence

Large well-characterized cohort (CATIE study) with objective THC measurement via hair testing, but cross-sectional design limits causal inference.

When this study was published

2026 study analyzing data from the CATIE trial.

The bigger picture

This finding is consistent with broader population studies showing lower obesity rates among cannabis users. In schizophrenia, where antipsychotic medications frequently cause metabolic side effects, understanding this association could be particularly valuable.

Questions still open

Is the metabolic benefit driven by THC itself, or by behavioral differences in cannabis users? Could targeted cannabinoid interventions help manage antipsychotic-induced metabolic side effects?

Common questions

Does cannabis protect against metabolic syndrome?

This study found an association between cannabis use and lower metabolic syndrome in schizophrenia, but the cross-sectional design cannot prove that cannabis causes the lower rates.

Why is metabolic syndrome important in schizophrenia?

Over half of people with schizophrenia develop metabolic syndrome, largely driven by antipsychotic medication side effects. It significantly increases cardiovascular disease risk and premature death.

Read the original research

Cannabis use and cardiometabolic risk in schizophrenia.

Schizophrenia research, 287, 54-62

View on PubMed ↗Publisher’s paper ↗

Citation

Paris, Jai; Laurendi, Olivia; Arnet, Victoria; Galletly, Cherrie. (2026). Cannabis use and cardiometabolic risk in schizophrenia.. Schizophrenia research, 287, 54-62. https://doi.org/10.1016/j.schres.2025.11.013